Health Care International - Data Demonstrate Orencia(R) (Abatacept) Increasingly Inhibits Progression Of Structural Damage Through Three Years In Adults With Rheumatoid Arthritis
Bristol-Myers Squibb Company (NYSE: BMY) announced results of radiographic analyses from the AIM (Abatacept in Inadequate responders to Methotrexate) study, which demonstrated that ORENCIA® (abatacept) provides significant inhibition in the progress
Comments